# National Scientific Center "M.D. Strazhesko Institute of Cardiology"

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/national-scientific-center-m-d-strazhesko-institute-of-cardiology/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 76 |
| Citations | 9,488 |
| City | Kyiv |
| Country | Ukraine |
| Description | National Scientific Center "M.D. Strazhesko Institute of Cardiology" is a research organisation in Kyiv, Ukraine. OpenAlex records 609 works and 9,488 citations for it. 1 researchers list it as their most recent affiliation. |
| Homepage | http://www.strazhesko.org.ua |
| OpenAlex ID | https://openalex.org/I4210151268 |
| Researchers | 1 |
| ROR ID | https://ror.org/054zhk838 |
| Type | facility |
| Works | 609 |

## University papers

- [Apixaban versus Warfarin in Patients with Atrial Fibrillation](https://scholariq.org/papers/apixaban-versus-warfarin-in-patients-with-atrial-fibrillation/)
- [Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials](https://scholariq.org/papers/comparison-of-the-efficacy-and-safety-of-new-oral-anticoagulants-with-warfarin/)
- [Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial](https://scholariq.org/papers/renal-outcomes-with-telmisartan-ramipril-or-both-in-people-at-high-vascular-risk/)
- [ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary](https://scholariq.org/papers/acc-aha-esc-guidelines-for-the-management-of-patients-with-atrial-fibrillation/)
- [Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency](https://scholariq.org/papers/beneficial-effects-of-long-term-intravenous-iron-therapy-with-ferric/)
- [Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation](https://scholariq.org/papers/antithrombotic-therapy-after-acute-coronary-syndrome-or-pci-in-atrial/)
- [Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome](https://scholariq.org/papers/apixaban-with-antiplatelet-therapy-after-acute-coronary-syndrome/)
- [Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization](https://scholariq.org/papers/prasugrel-versus-clopidogrel-for-acute-coronary-syndromes-without/)
- [Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial](https://scholariq.org/papers/ticagrelor-in-patients-with-diabetes-and-stable-coronary-artery-disease-with-a/)
- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)

## University researchers

- [Alexander Parkhomenko](https://scholariq.org/researchers/alexander-parkhomenko/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.